Background: Phosphatase and tensin                                   

homolog (PTEN) was identified as a 

tumor suppressor that is mutated in a 

large number of cancers at high frequency. 

It is one of the most commonly lost 

tumor suppressors in human cancer. 

During tumor development, mutations 

and deletions of PTEN occur that inactivate 

its enzymatic activity leading to increased 

cell proliferation and reduced cell death. 

Frequent genetic inactivation of PTEN 

occurs in glioblastoma, endometrial cancer, 

and prostate cancer; and reduced expression 

is found in many other tumor types such as 

lung and breast cancer.

Immunogen: A synthetic peptide from the 

internal region of PTEN which includes the 

mutation of R130G, human origin.

Tested applications: ELISA, WB

Recommended dilutions:

ELISA:  1:1000-1:5000

WB:     1:500-1:1000

Concentration: 1 mg/ml

Host: Mouse

Clonality: Monoclonal

Purity: Purified from ascites

Format: Liquid

Storage buffer: 

Preservative: no

Constituents: PBS (without Mg2+ and Ca2+), 

pH 7.4, 150 mM NaCl, 50% glycerol

Species Reactivity: Recognizes R130G mutant, 

but not wild-type PTEN from vertebrates.

Storage Conditions: Store at -20°C. Avoid